
==== Front
Cancer Med
Cancer Med
10.1002/(ISSN)2045-7634
CAM4
Cancer Medicine
2045-7634
John Wiley and Sons Inc. Hoboken

10.1002/cam4.70101
CAM470101
CAM4-2024-05-2741.R2
Research Article
Research Article
PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
Terán et al.
Terán Eduardo https://orcid.org/0000-0001-5643-6506
1 2
Lozano Rebeca 1 2
Rodríguez César A. https://orcid.org/0000-0003-3484-4829
1 2 carodriguez@saludcastillayleon.es

Abad Mar 2 3
Figuero Luis 1 2
Muñoz José Antonio 2 3
Cigarral Belén 1 2
Rodrígues Aline 1 2
Sancho Magdalena 2 3
Gómez M. Asunción 2 3
Morchón Daniel https://orcid.org/0009-0005-2987-3950
1 2
Montero Juan Carlos https://orcid.org/0000-0003-4773-053X
2 3 4
Sayagués José María https://orcid.org/0000-0003-0582-3500
2 3
Ludeña M. Dolores 2 3
Fonseca Emilio 1 2
1 Medical Oncology Department University Hospital of Salamanca Salamanca Spain
2 Institute of Biomedical Research of Salamanca (IBSAL) Salamanca Spain
3 Pathology Department University Hospital of Salamanca Salamanca Spain
4 Biomedical Research Networking Centers‐Oncology (CIBERONC) Madrid Spain
* Correspondence
César A. Rodríguez, Medical Oncology Department, University Hospital of Salamanca, Paseo de San Vicente, 58, Salamanca 37002, Spain.
Email: carodriguez@saludcastillayleon.es

05 9 2024
9 2024
13 17 10.1002/cam4.v13.17 e7010130 7 2024
28 5 2024
02 8 2024
© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction

Hotspots (HS) mutations in the PIK3CA gene may lead to poorer oncological outcomes and endocrine resistance in advanced breast cancer (BC), but their prognostic role in early‐stage disease remains controversial. The overall agreement within plasma and tissue methods has not been well explored. Our aim was to correlate tissue and plasma approaches and to analyze the prognostic impact of PIK3CA mutations (PIK3CAm) in HR+/HER2− BC.

Methods

A retrospective and unicentric analysis of PIK3CA mutational status in tissue and plasma samples by Cobas®PIK3CA Mutation Kit in patients with HR+/HER2− BC.

Results

We analyzed 225 samples from 161 patients with luminal BC. PIK3CA mutations were identified in 62 patients (38.5%), of which 39.6% were found in tissue and 11.8% in plasma. In advanced disease, plasma and tissue correlation rate was performed in 64 cases, with an overall agreement of 70.3%. Eighty patients were treated with CDK4/6 inhibitors + endocrine therapy. We observed a moderately worse progression‐free survival (PFS) in PIK3CAm versus wild‐type (WT) (24 m vs. 30 m; HR = 1.39, p = 0.26). A subanalysis was carried out based on exons 9 and 20, which showed a statistically poorer PFS in PIK3CAm exon 9 versus 20 population (9.7 m vs. 30.3 m; HR = 2.84; p = 0.024). Furthermore, detection of PIK3CAm in plasma was linked to a worse PFS vs PIK3CAm detection just in tissue (12.4 vs. 29.3; HR = 2.4; p = 0.08).

Conclusions

Our findings suggest the PIK3CA evaluation in tissue as the diagnostic method of choice, however, additional investigations are required to improve the role of liquid biopsy in the PIK3CA assessment. PIK3CAm show worse outcomes in advanced luminal BC, especially in exon 9 mutation carriers, despite visceral involvement, prior exposure to endocrine therapy or detection of PIK3CAm in plasma, with an unclear prognosis in early‐stage disease. Nonetheless, this should be validated in a prospective cohort study.

PIK3CA gene assessment in tissue remains the main diagnostic approach. The use of highly sensitive techniques or the timing of peripheral blood collection could better characterize the contribution of liquid biopsy in the identification of PIK3CA mutations. Despite the limited sample size, PIK3CAm may lead to worse outcomes in advanced luminal breast cancer (BC), particularly showing a significantly poorer prognosis in exon 9 mutation carriers, independent of visceral involvement, and plasma detection. However, their impact remains unclear in early‐stage BC, and these findings need confirmation in a larger prospective and separate cohort.

ctDNA
cyclin inhibitors
luminal breast cancer
PIK3CA
tissue
Roche Diagnostics 10.13039/100016545 Costs related to the analysis of samples source-schema-version-number2.0
cover-dateSeptember 2024
details-of-publishers-convertorConverter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:05.09.2024
Terán E , Lozano R , Rodríguez CA , et al. PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer. Cancer Med. 2024;13 :e70101. doi:10.1002/cam4.70101

M. Dolores Ludeña and Emilio Fonseca should be considered as joint senior authors.
==== Body
pmcINTRODUCTION

Phosphatidylinositol 3‐kinases (PI3Ks) play a critical role in several processes involved in tumor progression, such as growth, cell metabolism, and survival through the PI3k/AKT/mTOR pathway. 1 , 2 , 3 Multiple investigations have revealed that this route is upregulated in approximately 60%–75% of tumors, including breast cancer (BC). 4 , 5

Activating mutations in the PIK3CA (PIK3CAm) gene directly alter the function of the PI3 kinase protein, causing abnormal activation of the PI3 kinase signaling pathway and promoting cancer progression. In contrast, neutral somatic mutations are common variants found in the general population that have minimal impact on protein function. 6

Hotspot (HS) mutations in PIK3CA are detected in approximately 30%–40% of luminal BCs, 7 resulting in hyperactivation of the catalytic subunit (p110α) of phosphatidylinositol‐3‐kinase (PI3K). PIK3CAm most commonly occur at three HS sites: E542K and E545K in exon 9 (helical domain), and H1047R in exon 20 (kinase domain). 8

The implications of PIK3CAm and patient outcomes remain controversial. Some studies have suggested poorer clinical outcomes in advanced disease, resulting in lower overall survival (OS) due to the constitutive activation of the PI3K/AKT/mTOR pathway, which promotes cell growth and invasion, and increased resistance to endocrine therapy, chemotherapy, and some targeted therapies in PIK3CAm carriers. 9 , 10

On the other hand, PIK3CAm in early BC (eBC) has also been reported by some authors to be associated with increased recurrence‐free survival 11 and responsiveness to hormonal therapy. Although its prognostic role in early stage is more debated 12 , 13 and may vary based on clinical circumstances and the specific treatment regimen employed.

Recently, the prognostic impact of PIK3CAm in patients treated with cyclin inhibitors has been reported, 14 identifying the presence of PIK3CAm as a promising predictive biomarker of resistance to CDK4/6 inhibitors.

Based on the phase III trial, SOLAR‐1, 15 PIK3CAm have reached level 2 evidence for predicting benefit, according to the Magnitude of Clinical Benefit Scale by ESMO, from fulvestrant combined with alpelisib, an alpha‐specific PI3K inhibitor in patients with advanced HR+/HER2− BC, who had previously progressed to a previous line of endocrine therapy, showing a significantly higher median PFS compared to placebo plus fulvestrant (HR = 0.65 [95% CI, 0.50–0.85], p < 0.001). Hence, with the recent approval of alpelisib for BC patients whose tumors harbor PIK3CAm, the proficiency testing for PIK3CAm analysis is essential.

In addition, plasma‐derived circulating tumor DNA (ctDNA) offers real‐time insight into genetic alterations and a non‐invasive view of tumor heterogeneity. The determination of PIK3CAm in plasma could provide critical information and discriminate patients who would benefit from treatment with PIK3CA inhibitors. Also, the plasma detection rate of PIK3CAm in BC is highly variable, ranging from 26% to 93%, 16 and correlation rate among testing methods (tissue and plasma) has not been well explored. Our aim was to correlate tissue and plasma approaches and to analyze the prognostic impact of PIK3CA mutations (PIK3CAm) in HR+/HER2− BC.

1 METHODS

1.1 Study design and participants

This is a retrospective, unicentric, and observational analysis of PIK3CA mutational status in tissue and plasma in patients with HR+/HER2− BC from February 2021 to April 2023 in the University Hospital of Salamanca (HUSA).

Samples obtained from patients with HR+/HER2− BC were collected from tissue (primary tumor or metastases) and plasma. Liquid biopsy was obtained exclusively from patients with metastatic disease. The patients met the following criteria: histopathological confirmed diagnosis of BC, with complete clinical and histological data.

1.2 Technical analysis of PIK3CA in plasma and tissue

DNA extraction from formalin‐fixed paraffin‐embedded (FFPE) tumor tissue and liquid biopsy was conducted using Cobas® DNA/cfDNA sample preparation kit (Roche Diagnostics), according to the manufacturer's guidelines. A comprehensive analysis of the technical process of tissue and plasma sample extraction is included in the Data S1.

The DNA obtained from FFPE and liquid biopsy samples were used to analyze 17 mutations across exons 1, 4, 7, 9, and 20 of the PIK3CA gene (Roche Diagnostics) using the Cobas® PIK3CA Kit (Cobas® platform, Roche Diagnostics). 17

The Cobas® PIK3CA Mutation Test platform is specifically designed to differentiate activating mutations in the PIK3CA gene from neutral somatic mutations and germline polymorphisms. It focuses on recognized mutation HS within PIK3CA (associated with functional changes in the PI3 kinase protein, which can lead to abnormal activation of the PI3 kinase signaling pathway), utilizing an extensive database of validated mutations, rigorous quality control measures, and real‐time PCR technology for targeted amplification and sequencing of pertinent gene regions. Detailed clinical reports are generated to provide precise information for making informed therapeutic decisions based on the mutation profile identified in the patient's PIK3CA gene. 17

1.3 Study outcomes

Clinical assessment criteria, such as response rate, disease‐free survival (DFS), or metastasis‐free interval and progression‐free survival (PFS) were analyzed.

We correlated both diagnostic methods (tissue and plasma) and examined the discordant cases and patient characteristics. We analyzed clinical outcomes in PIK3CAm and wild‐type (WT) populations in terms of metastasis‐free interval and PFS during treatment with CDK4/6 inhibitors, according to HS mutations (exon 9 vs. 20), visceral involvement, metastatic sites, and detection in plasma.

1.4 Statistical analysis

A descriptive analysis of the clinicopathological features of the population was performed according to PIK3CA status (PIK3CAm vs. WT). To assess the quality of the statistical data for group differentiation, we used Student's t‐test and Mann–Whitney U‐test for normally and abnormally distributed continuous variables, respectively. SPSS v.22 (IBM Corp., Armonk, NY, USA) was applied to calculate continuous variables and measures of central tendency, such as mean and standard deviation.

Frequencies and percentages were indicated as dichotomous variables using Pearson's X 2 test. The statistical significance of the differences in survival was determined by the Mantel–Cox test (log‐rank test) and the Kaplan–Meier method. Cox regression models were used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) for PFS. Multivariate analysis of prognostic factors for PFS was carried out using multivariate Cox regression models. Results were defined as significant when two‐sided p‐values were <0.05.

2 RESULTS

2.1 Mutational spectrum

We included 161 patients, 71 with eBC and 90 patients with advanced disease. A total of 225 samples from 161 patients were analyzed: 149 tissue samples and 76 plasma samples. Mutations in the PIK3CA gene (n = 69) were identified in 62 patients (38.5%). Of these, 39.6% were in tissue (59 patients) and 11.8% were in plasma (9 patients). Seven patients (11.3%) had >1 activating mutation in the PIK3CA gene. Plasma was obtained exclusively from patients with advanced disease.

The most frequent PIK3CAm were those located in the three HS: the tyrosine kinase domain of exon 20; H1047X (44.9%), followed by mutations in the helical domain of exon 9 (37.7%), E545X (20%), E542K (13%), and Q546X (4.7%). Rare mutations in exon 7 were described in 10.1% (C420R) and in exon 4 in 7.2% (N345K).

We reported a similar PIK3CA mutational rate in eBC; 38% (27 out of 71 patients) and in advanced disease; 38.8% (35 out of 90 patients), OR = 0.96 (95% CI, 0.51–1.83); p = 0.91. Furthermore, according to the site of PIK3CAm determination, analysis was performed on primary tumor tissue in 121 subjects (81.2%) and on metastatic tissue in 28 patients (18.8%), including hepatic (n = 12), pulmonary (n = 4), soft tissue (n = 6), lymph node (n = 4), ovarian (n = 1), and adrenal (n = 1). We did not observe a significantly higher proportion of PIK3CAm in primary tumor tissue versus metastases [40.5% vs. 35.7%, OR = 1.23 (95% CI, 0.52–2.88); p = 0.64].

2.2 Plasma–tissue correlation analysis

We conducted a plasma–tissue correlation study in 64 metastatic patients for whom paired samples were available. We found PIK3CAm in 28 (43.8%). The overall tissue–plasma correlation rate was 70.3%, with a positive agreement in 9 of 28 patients (32.1%). Interestingly, a discordant result was observed in 19 cases (29.7%) with the detection of PIK3CAm in tissue but not in plasma, as shown in Table 1.

TABLE 1 Tissue and plasma correlation analysis of PIK3CAm carriers.

	Tissue		
Mutated	WT	Total	
Plasma	
Mutated	9 (32.1%)	0 (0%)	9 (14.1%)	
WT	19 (67.8%)	36 (100%)	55 (85.9%)	
Total	28 (100%)	36 (100%)	64 (100%)	
	Positive agreement: 9/28 (32.1%)	
	Negative agreement: 36/36 (100%)	
	Overall agreement: 45/64 (70.3%)	
Bold values indicate that 9 (32.1%) of cases have mutations detected in both tissue and plasma, demonstrating a positive correlation. Meanwhile, 36 cases (100%) showed no mutations in either tissue or plasma, indicating complete negative concordance.

For patients with paired tissue‐plasma studies (n = 64), PIK3CA determination was performed in primary tumor tissue for 60.9% and in metastases for 39.1%. We observed a similar proportion of PIK3CAm in primary tumor tissue or metastases [41% vs. 36%, OR = 1.23 (95% CI, 0.44–3.49); p = 0.69].

The timing of the samples was characterized by the median time (in days) between tissue biopsy and plasma collection. For the overall population, we observed a median interval of 779.5 days with an interquartile range (IQR) of 1150. In patients with PIK3CAm, this interval extended to 1256 days with an IQR of 2309, while for those with PIK3CA WT, it was 721 days with an IQR of 954. We found no significant association between the timing of sample collection and the presence of PIK3CAm; p = 0.54.

We conducted an analysis to identify the characteristics associated with the PIK3CAm detection in plasma. PIK3CAm detection in plasma was more frequent in population with ≥3 metastatic sites [66.7% vs. 31.6%, OR = 4.33 (95% CI, 0.79–23.5); p = 0.08], visceral involvement [66.7% vs. 47.4%, OR = 0.53 (95% CI, 0.91–3.14); p = 0.43] and sample collection during disease progression [66.7% vs. 47.4%, OR = 2.22 (95% CI, 0.43–11.60); p = 0.44]. Specifically, PIK3CAm was detected in plasma in 50% of patients with ≥3 metastatic sites and in 40% of patients with visceral involvement. Also, it should be noted that plasma collection during disease progression was performed in 54.7% of patients (35 out of 64 patients).

2.3 Patient characteristics

Clinicopathological characteristics are listed in Table 2. One hundred sixty‐one patients were included, with a median age of 54 years [21–91]. Seventy‐one patients with eBC and 90 patients with advanced disease were analyzed. According to histological subtype, we observed a significantly higher proportion of BC with lobular histology in PIK3CAm carriers versus WT [18.1% vs. 4.1%, OR = 5.12 (95% CI, 1.55–16.89); p = 0.007]. Other clinicopathological features reflected in Table 2 showed a similar proportion between both groups (PIK3CAm vs. WT). Smaller tumors (<50 mm), less nodal involvement, lower Ki‐67 index, and histological grade were observed in PIK3CAm versus WT population, although not statistically significant.

TABLE 2 Clinical and pathological features of carriers and non‐carriers of PIK3CAm in our sample.

		PIK3CAm	PIK3CA WT	p‐value	
(n = 62)%	(n = 99)%	
Age; median [min‐max]	55 [24–90]	56 [33–91]		
Histological type	Ductal	47 (77%)	81 (83.5%)	p = 0.007	
Lobular	11 (18.1%)	4 (4.1%)	
Others	3 (4.9%)	12 (12,4%)	
Histological grade	1	18 (31.6%)	15 (16.1%)	p = 0.06	
2	33 (57.9%)	62 (66.7%)	
3	6 (10.5%)	16 (17.2%)	
Ki67 (%)	<14%	31 (53.4%)	42 (44.2%)	p = 0.26	
≥14%	27 (46.6%)	53 (55.8%)	
Her2	Negative/0	42 (72.4%)	57 (60.6%)	p = 0.13	
1+/2+	16 (27.6%)	37 (39.4%)	
Tumor size	<50 mm	42 (73.7%)	79 (82,3%)	p = 0.21	
≥50 mm	15 (26.3%)	17 (17.7%)	
Nodes (N)	N0	19 (37.3%)	30 (33.3%)	p = 0.63	
N+	32 (62.7%)	60 (66.7%)	
Debut M1	Yes	13 (37.1%)	21 (38.2%)	p = 0.92	
No	22 (62.9%)	34 (61.8%)	
Visceral involvement	Yes	26 (74.3%)	40 (72.7%)	p = 0.87	
No	9 (25.7%)	15 (27.3%)	
Note: M1: advanced disease.

Abbreviation: WT, wild‐type.

Bold values indicate a significant association between PIK3CAm and the histological type of breast cancer. Notably, patients with PIK3CAm exhibit a higher prevalence of lobular histology (18.1%) compared to those without the mutation (4.1%). This difference is statistically significant, as indicated by a p‐value of 0.007.

2.4 Prognostic value of PIK3CAm

In the overall population assessed for DFS (n = 127); 78 patients were PIK3CAm (61.4%) and 49 were PIK3CA WT (38.6%), excluding those with advanced stage at onset. During follow‐up, 56 patients developed metastatic disease, while 71 did not experience recurrences.

Among the 78 PIK3CA WT patients, 44 (56.4%) did not experience recurrence, compared to 27 out of 49 PIK3CAm patients (55.1%). We did not observe a higher proportion of recurrences in the PIK3CAm population compared to WT [44.9% vs. 43.6%; p = 0.89, OR = 1.05 (95% CI, 0.51–2.17)]. Excluding patients who did not experience recurrences (censored cases), we observed similar DFS in the PIK3CAm vs WT population [90.7 m vs. 89.9 m, HR = 0.98 (95% CI, 0.56–1.69); p = 0.94], as illustrated in Figure 1.

FIGURE 1 Disease‐free survival (DFS) according to the molecular status of PIK3CA gene.

Regarding HS mutations, although not statistically significant, we observed longer DFS in the PIK3CAm exon 20 compared to exon 9 population [112.4 m vs. 107.7 m, HR = 1.67 (95% CI, 0.57–4.91); p = 0.35].

Univariate and multivariate analysis were conducted to evaluate the impact of PIK3CAm mutational status on DFS in eBC patients. Multivariate analysis in Figure 2, identified nodal involvement as an independent prognostic factor for DFS in eBC [HR = 2.76 (95% CI, 1.1–6.94); p = 0.03].

FIGURE 2 Multivariate analysis evaluating the prognostic impact in terms of DFS of clinical and molecular variables in eBC patients.

Additionally, we reported shorter DFS in patients with HER2− low [HR = 2.2 (95% CI, 0.95–5.1); p = 0.07] and grade 3 tumors [HR = 2.18 (95% CI, 0.9–5.28); p = 0.08].

2.4.1 PIK3CA evaluation in population treated with cyclin inhibitors

In addition, in metastatic disease, 80 patients received treatment with CDK4/6 inhibitors + endocrine therapy: 61 in the first line and 19 in the second line. We observed reduced PFS in PIK3CAm carriers versus WT [24 m vs. 30 m; HR = 1.39 (95% CI, 0.7–2.4); p = 0.26]. Detailed information about clinical outcomes in PIK3CAm carriers and the WT population with cyclin inhibitors is provided in Figure 3.

FIGURE 3 Outcomes according to progression‐free survival (PFS) in PIK3CAm and WT patients with cyclin inhibitor treatment.

We observed a similar response rate in PIK3CAm vs WT [68.8% vs. 77.1%, OR = 0.65 (95% CI, 0.24–1.79); p = 0.41]. In addition, we reported a higher proportion of visceral involvement in PIK3CAm versus WT [75% vs. 68.8%, OR = 1.36 (95% CI, 0.49–3.73); p = 0.54], and a significantly poorer PFS in patients with visceral involvement [21.6 m vs. 57.7 m; p = 0.001, HR = 3.6 (95% CI, 1.61–8.07); p = 0.002] and in those with metastatic sites ≥3 [20.2 m vs. 35.6 m, HR = 2.0 (1.13–3.59); p = 0.02]. Based on visceral involvement and the number of metastatic locations, we did not observe a significant prognostic impact associated with PIK3CAm: HR = 1.13 (95% CI, 0.63–2.04); p = 0.69. An extensive analysis of the prognostic impact of visceral involvement in PIK3CAm and WT populations treated with cyclin inhibitors is included in the Data S1.

Focusing on the PIK3CAm population (n = 32), we identified worse outcomes in PFS in population with visceral involvement [21.9 m vs. 30.1 m; p = 0.08, HR = 2.82 (95% CI, 0.6–12.3); p = 0.14], as presented in Figure 4.

FIGURE 4 Progression‐free survival (PFS) in the PIK3CAm population regarding visceral involvement.

In addition, PIK3CAm detection in plasma was related to a worse PFS compared with those cases where PIK3CAm was identified exclusively in tissue [12.4 m vs. 29.3 m; HR = 2.4 (95% CI, 0.8–6.5), p = 0.08], as reflected in Figure 5. Stratifying by visceral involvement and number of metastatic sites (≥3), we did not observe a significant prognostic impact of PIK3CAm in plasma; HR = 2.04 (0.59–7.02); p = 0.26.

FIGURE 5 Progression‐free survival (PFS) in PIK3CAm regarding PIK3CA status in ctDNA.

In patients undergoing treatment with cyclin inhibitors, we conducted a subanalysis focusing on PIK3CAm in exons 9 (n = 15) and 20 (n = 12), comprising a total of 27 subjects.

In 22 patients, cyclin inhibitors were used as first‐line treatment, while in 5 cases, prior exposure to endocrine therapy for advanced disease was reported. Interestingly, we observed that patients with PIK3CAm on exon 9 had a significantly poorer PFS versus those with PIK3CAm on exon 20 [9.7 m vs. 30.3 m; HR = 2.84 (95% CI, 1.1–7.4), p = 0.024]. The results of the exon analysis are summed up in Figure 6. No significant differences were observed in response rates between PIK3CAm and WT population; [73.3% vs. 75%; OR = 0.92 (95% CI, 0.16–5.21); p = 0.92].

FIGURE 6 Clinical outcomes in PIK3CAm patients comparing exon 9 versus 20 carriers.

Even though we reported a trend to worse PFS in patients with prior exposure to endocrine therapy in advanced disease [HR = 2.73 (95% CI, 0.87–9.32); p = 0.07], visceral involvement [HR = 2.92 (95% CI, 0.65–13.18); p = 0.16], and plasma detection of PIK3CAm [HR = 1.05 (95% CI, 0.33–3.61); p = 0.92], in a multivariate analysis, mutations in exon 9 were an independent poor prognostic factor; HR = 2.87 (95% CI, 1.02–8.55); p = 0.049.

3 DISCUSSION

In our research, we found PIK3CAm in 38.5% of BC (62 patients), 77.9% occurring at the three HS (E542K and E545K at exon 9 and H1047R at exon 20). Our results agree with those previously reported: PIK3CAm rate ranges from 30% to 40% of BC 7 and is more frequent in HR+ disease. Similar mutation rates have been reported in advanced disease (between 30% and 40%) 15 , 18 and in the three HS mentioned above (70%).

Due to the clinically significant results of PIK3CA inhibitors in metastatic BC patients 15 and the spatial heterogeneity of PIK3CA expression within BC (from primary tumor to metastases 19 ), the reliable screening for PIK3CAm is still of paramount importance, as it could guide clinicians' decision making.

We found no significant differences in the PIK3CAm status (PIK3CAm vs. WT) between eBC and metastatic disease (38.0% vs. 38.8%; p = 0.91). Similarly, no differences were reported according to the biopsy location, whether from the primary tumor or metastasis. As presented in our study, there is a similar PIK3CAm rate in primary tumors and metastases 20 and discordances are relatively low (approximately 10%). Along with that, Juric et al., 21 reported that the rate of PIK3CA WT eBC that changed to PIK3CAm is quite unusual, which could explain a stable incidence between early and late‐stage BC.

According to the screening of PIK3CAm, detection in fresh tumor samples and ctDNA depends on analytical and methodological reasons, which possibly affects clinical utility validation. 22

We performed a plasma and tissue correlation study in 64 metastatic patients, with an overall correlation rate of 70.3%. It is noteworthy that 19 out of 28 patients had a discordant result: PIK3CAm was detected in tissue and missing in plasma.

Limited studies have explored the agreement of ctDNA vs tissue‐based methods. They show a widely variable concordance rated (26%–93%) between the two approaches 16 , 23 , 24 due to low or non‐tumor shedding, technical difficulties or tumor heterogeneity.

In our study, we reported a moderate discordance rate (29%) that could be explained by the sensitivity of the technique used for ctDNA testing 25 (Cobas®PIK3CA Kit) with an analytical sensitivity of 0.7%–3.5%. 17 This test provides a significantly lower detection capacity than other techniques, such as exosome‐derived DNA analysis, next generation sequencing or digital PCR (detection of PIK3CAm below 0.1%).

Also, we observed a higher plasma correlation in patients with visceral involvement, ≥3 metastatic sites, as well as collection during disease progression, which would translate into a higher tumor burden and ctDNA. 25 This is in line with what has been published by Oliveira et al., 26 who identified greater cost‐effectiveness in detecting mutations in disease progression status.

In relation to the clinicopathological characteristics, we observed a significantly higher proportion of BC with lobular histology in PIK3CAm population (18.1% vs. 4.1%; p = 0.007). Nonetheless, most studies have been carried out on invasive ductal BC, and only sporadic cases of less common histologies with better prognoses have been explored for PIK3CA abnormalities. 27 Based on some reports, the frequency of PIK3CAm was particularly high (up to 46% of cases) in the lobular histology, with one of the highest incidences recorded so far for different types of human neoplasms. 28

Although in our study we did not report significant differences in other clinicopathological features, we observed a trend toward smaller tumors, with less lymph node involvement and a lower Ki‐67 index. This is in line with Kalinsky et al., 29 who described the association with good prognostic features in PIK3CAm eBC, including lymph node negativity (p = 0.03), lower tumor stage (p = 0.02) and lower grade (p < 0.001).

In addition, PIK3CAm seems to display differential prognostic value in eBC; as a favorable prognostic factor 29 but questionable by some authors, 30 whereas, in metastatic setting, it has been strongly associated with poorer OS and resistance to chemo and endocrine therapies in advanced disease. 18 , 31 In the study published by Dr. Kok and colleagues, 32 no prognostic impact of somatic PIK3CAm was observed in women with HR+/HER2− eBC on DFS and OS. In line with this, we did not observe in our population a higher DFS (time to metastases) in PIK3CAm vs WT (p = 0.94). According to our multivariate analysis, PIK3CA status did not appear to be as crucial as lymph node involvement (HR = 2.76; p = 0.03) or tumor grade (HR = 2.18; p = 0.08) in relapsing disease.

Based on the endocrine resistance conferred by PIK3CAm, we described in advanced disease worse PFS in PIK3CAm patients treated with cyclin inhibitors (21.9 m vs. 30.1 m; p = 0.08). This detrimental effect was greater in patients with visceral involvement and plasma detection of PIK3CAm and in exon 9 PIK3CAm carriers. Our results are along with those presented by Del Re et al., 14 in which they describe that PIK3CAm detection in liquid biopsy correlates with a poorer PFS in population with metastatic BC undergoing treatment with CDK4/6 inhibitors (7.44 vs. 12.9 months, p = 0.01).

However, there is still controversy regarding the prognosis associated with different PIK3CAm. 12 , 13 Our data confirm the results of Barbareschi and colleagues, 13 in which exon 9 PIK3CAm were strongly related to early recurrence and death compared with exon 20 PIK3CAm with a better prognosis.

While these studies suggest poorer outcomes of certain PIK3CAm in the pre‐cyclin inhibitor era, our research supports the potential deleterious effect of mutations in exon 9 during CDK4/6 inhibitors treatment.

Therefore, this population represents an unmet clinical need. Its identification could be critical for guiding future therapeutic decisions and could be reconsidered as a potential predictive biomarker of resistance to CDK4/6 inhibitors.

In addition, a similar range of benefits has been reported with the PIK3CA inhibitor (alpelisib) in exons 9 and 20 PIK3CAm carriers, in agreement with the outcomes of the phase 3 SOLAR‐1 trial, 15 representing a potential therapeutic option in this poorer prognosis population.

4 CONCLUSIONS

In conclusion, our findings suggest the PIK3CA evaluation in tissue as the diagnostic method of choice, however, additional investigations are warranted to better define the role of liquid biopsy in the PIK3CA assessment. Improvements in liquid biopsy techniques for detecting PIK3CAm, combined with careful timing and selection of clinicopathological characteristics, could significantly enhance detection sensitivity rates. Despite the study's limited sample size, PIK3CAm appear to correlate with poorer outcomes in advanced luminal BC patients treated with CDK4/6 inhibitors; significantly worse in exon 9 mutation carriers, regardless of visceral involvement and plasma detection, highlighting an urgent and unmet clinical concern. In early‐stage disease, PIK3CAm did not demonstrate a significant prognostic impact. These findings underscore the need for validation in a larger, prospective cohort study.

AUTHOR CONTRIBUTIONS

Eduardo Terán: Conceptualization (lead); formal analysis (lead); methodology (lead). Rebeca Lozano: Conceptualization (lead); data curation (lead); formal analysis (lead); methodology (equal). César A. Rodríguez: Conceptualization (equal); data curation (equal); formal analysis (equal); project administration (lead). Mar Abad: Conceptualization (equal); investigation (equal); methodology (equal); project administration (equal). Luis Figuero: Data curation (equal); investigation (equal); supervision (equal). José Antonio Muñoz: Data curation (equal); investigation (equal); methodology (equal). Belén Cigarral: Data curation (equal); investigation (equal). Aline Rodrígues: Data curation (equal); investigation (equal); methodology (equal). Magdalena Sancho: Data curation (equal); formal analysis (equal); investigation (equal). M. Asunción Gómez: Formal analysis (equal); methodology (equal). Daniel Morchón: Data curation (equal); formal analysis (equal); methodology (equal). Juan Carlos Montero: Formal analysis (equal); methodology (equal); project administration (equal). José María Sayagués: Formal analysis (equal); methodology (equal). M. Dolores Ludeña: Funding acquisition (lead); investigation (equal); methodology (equal); project administration (equal). Emilio Fonseca: Project administration (lead).

FUNDING INFORMATION

The project has been funded by Roche Diagnostics, S.L. within the research study “Characterization and comparison of the mutational status of the PIK3CA gene between the primary tumor, metastatic tissue, and peripheral blood of patients with advanced breast cancer at Complejo Asistencial Universitario de Salamanca (CAUSA) (2021–2023).”

ETHICS STATEMENT

All procedures performed in studies with human subjects conformed to the ethical guidelines of the institutional and/or national research committee and to the 1964 Declaration of Helsinki and its subsequent modifications. The research was also endorsed by the Bioethics Committee of the University Hospital of Salamanca.

CONSENT

In addition, informed consent was provided by the subjects involved in the study. All procedures were conducted according to the appropriate standards. Also, all participants in this study have consented to the publication of this manuscript.

Supporting information

Data S1:

ACKNOWLEDGMENTS

The authors wish to thank the patients, their families, and all the investigators who participated in this research. Medical editorial staff was supported by the Oncology and Pathology Departments of the University Hospital of Salamanca. Also, we received technical support from the Institute of Biomedical Research of Salamanca and from Roche Diagnostics, S.L. Nevertheless, final responsibility for the opinions, conclusions, and interpretation of the data rests with the authors.

DATA AVAILABILITY STATEMENT

Data sets used and analyzed during the present study are available from the corresponding author upon reasonable request to safeguard the confidentiality of the patient's clinical data.
==== Refs
REFERENCES

1 Amzel LM , Huang CH , Mandelker D , Lengauer C , Gabelli SB , Vogelstein B . Structural comparisons of class I phosphoinositide 3‐kinases. Nat Rev Cancer. 2008;8 (9 ):665‐669.18633356
2 Courtney KD , Corcoran RB , Engelman JA . The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28 (6 ):1075‐1083.20085938
3 Liu P , Cheng H , Roberts TM , Zhao JJ . Targeting the phosphoinositide 3‐ kinase pathway in cancer. Nat Rev Drug Discov. 2009;8 :627‐644.19644473
4 Lee JJ , Loh K , Yap YS . PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015;12 (4 ):342‐354.26779371
5 Forbes SA , Bindal N , Bamford S , et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011;39 (Database issue ):D945‐D950.20952405
6 Thorpe LM , Yuzugullu H , Zhao JJ . PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15 (1 ):7‐24. doi:10.1038/nrc3860 25533673
7 Reinhardt K , Stückrath K , Hartung C , et al. PIK3CA‐mutations in breast cancer. Breast Cancer Res Treat. 2022;196 (3 ):483‐493.36279023
8 Martínez‐Sáez O , Chic N , Pascual T , et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020;22 (1 ):45.32404150
9 Aleskandarany MA , Rakha EA , Ahmed MA , et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat. 2010;122 (1 ):45‐53.19701705
10 Mangone FR , Bobrovnitchaia IG , Salaorni S , Manuli E , Nagai MA . PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo). 2012;67 (11 ):1285‐1290.23184205
11 Cizkova M , Susini A , Vacher S , et al. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2‐based subgroups. Breast Cancer Res. 2012;14 (1 ):R28.22330809
12 Lai YL , Mau BL , Cheng WH , Chen HM , Chiu HH , Tzen CY . PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008;15 (4 ):1064‐1069. doi:10.1245/s10434-007-9751-7 18183466
13 Barbareschi M , Buttitta F , Felicioni L , et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res. 2007;13 :6064‐6069.17947469
14 Del Re M , Crucitta S , Lorenzini G , et al. PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients. Pharmacol Res. 2021;163 :105241. doi:10.1016/j.phrs.2020.105241 33049397
15 André F , Ciruelos E , Rubovszky G , et al. Alpelisib for PIK3CA‐mutated, hormone receptor‐positive advanced breast cancer. N Engl J Med. 2019;380 (20 ):1929‐1940. doi:10.1056/NEJMoa1813904 31091374
16 Nakauchi C , Kagara N , Shimazu K , et al. Detection of TP53/PIK3CA mutations in cell‐free plasma DNA from metastatic breast cancer patients using next generation sequencing. Clin Breast Cancer. 2016;16 (5 ):418‐423.27265061
17 Roche . Cobas® PIK3CA Mutation Test for Use on the Cobas® 4800 System. Instructions for Use. Roche Molecular Systems, Inc; 2017.
18 Mosele F , Stefanovska B , Lusque A , et al. Outcome and molecular landscape of patients with PIK3CA‐mutated metastatic breast cancer. Ann Oncol. 2020;31 (3 ):377‐386.32067679
19 Jensen JD , Laenkholm AV , Knoop A , et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2011;17 (4 ):667‐677.20940279
20 Rosin J , Svegrup E , Valachis A , Zerdes I . Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta‐analysis. Breast Cancer Res Treat. 2023;201 (2 ):161‐169.37392328
21 Juric D , Ciruelos E , Rubovszky G , et al. Abstract GS3‐08: Alpelisib + fulvestrant for advanced breast cancer: subgroup analyses from the phase III SOLAR‐1 trial. Cancer Res. 2019;79 :GS3‐08.
22 Fusco N , Malapelle U , Fassan M , et al. PIK3CA mutations as a molecular target for hormone receptor‐positive, HER2‐negative metastatic breast cancer. Front Oncol. 2021;25 (11 ):644737.
23 Chae YK , Davis AA , Jain S , et al. Concordance of genomic alterations by next‐generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer. Mol Cancer Ther. 2017;16 (7 ):1412‐1420.28446639
24 Kodahl AR , Ehmsen S , Pallisgaard N , et al. Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer. Mol Oncol. 2018;12 (6 ):925‐935.29689598
25 Vollbrecht C , Hoffmann I , Lehmann A , et al. Proficiency testing of PIK3CA mutations in HR+/HER2‐breast cancer on liquid biopsy and tissue. Virchows Arch. 2023;482 (4 ):697‐706.36367572
26 Olivera‐Salguero R , Seguí E , Cejalvo JM , et al. HOPE (SOLTI‐1903) breast cancer study: real‐world, patient‐centric, clinical practice study to assess the impact of genomic data on next treatment decision‐choice in patients with locally advanced or metastatic breast cancer. Front Oncol. 2023;28 (13 ):1151496.
27 Campbell IG , Russell SE , Choong DY , et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64 :7678‐7681.15520168
28 Buttitta F , Felicioni L , Barassi F , et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol. 2006;208 (3 ):350‐355.16353168
29 Kalinsky K , Jacks LM , Heguy A , et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15 (16 ):5049‐5059.19671852
30 Li SY , Rong M , Grieu F , Iacopetta B . PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 2006;96 (1 ):91‐95. doi:10.1007/s10549-005-9048-0 16317585
31 Zardavas D , Te Marvelde L , Milne RL , et al. Tumor PIK3CA genotype and prognosis in early‐stage breast cancer: a pooled analysis of individual patient data. J Clin Oncol. 2018;36 (10 ):981‐990.29470143
32 Kok VC , Huang TY , Hsu YC , Chang YC , Yang PS . Select gene mutations associated with survival outcomes in ER‐positive ERBB2‐negative early‐stage invasive breast cancer: a single‐institutional tissue bank study. Cancer Med. 2024;13 (14 ):e70035.39031010
